In 1993, Rusch and colleagues demonstrated that the protein expression of EGFR is significantly increased in 45% of tumour lesions from NSCLC patients, while TGFα was overexpressed in 61% of those tumours. The gene discussed is TGFA; the disease is neoplasm.